期刊文献+

硼替佐米调控内质网应激诱导人急性T淋巴细胞白血病细胞株凋亡的机制探讨 被引量:3

The mechanism of Bortezomib on apoptosis of human T cell acute lymphoblastic leukemia by modulation of endoplasmic reticulum stress
下载PDF
导出
摘要 目的:探讨硼替佐米对人急性T淋巴细胞白血病(T cell acute lymphoblastic leukemia,T-ALL)细胞株Molt-4细胞凋亡的影响。方法:硼替佐米(0、100、200和400 nmol/L)处理人急性T淋巴细胞白血病细胞株Molt-4细胞后,运用MTT法测定Molt-4细胞活力;使用Hoechst 33258染色法观察凋亡细胞形态;采用荧光定量PCR法测定Bax以及Bip mRNA水平;运用Western blot法测定Bax以及Bip蛋白水平。结果:100、200和400 nmol/L的硼替佐米处理Molt-4细胞24 h后,可浓度依赖性地降低细胞活力。100、200和400 nmol/L的硼替佐米作用细胞24 h后,Molt-4细胞核发生固缩或裂解。硼替佐米(100、200和400 nmol/L)处理细胞24 h后,Molt-4细胞的Bax mRNA和蛋白表达水平明显增加且可显著上调Bip mRNA和蛋白表达水平。结论:硼替佐米可诱导人急性T淋巴细胞白血病细胞株Molt-4细胞凋亡,作用机制可能与它调控内质网应激有关。 Objective:To investigate the role of Bortezomib on cell apoptosis of human T cell acute lymphoblastic leukemia cell line Molt-4 cells.Methods:After adminstration of Molt-4 cells with different concentrations of Bortezomib(100,200 and 400 nmol/L)for 24 h,cell viability was detected using MTT assay.The morphological of apoptotic cells was observed under a fluorescence microscope using Hoechst 33258 staining.The expression levels of Bax as well as Bip mRNA were measured by quantitative real-time PCR.The expression levels of Bax as well as Bip protein were measured by Western blot.Results:Compared with the 0 nmol/L group,Bortezomib obviously decreased the viability of Molt-4 cells in a dose dependent way.Additionally,after treating with Bortezomib(100,200 and 400 nmol/L),the occurrence of apoptotic morphology and the expression levels of Bax mRNA as well as protein in Molt-4 cells were significantly elevated.The expression levels of Bip mRNA as well as protein in Molt-4 cells were obviously increased after treating by Bortezomib for 24 h.Conclusion:Bortezomib can induce cell apoptosis of human T cell acute lymphoblastic leukemia cell line Molt-4 cells,which may be associated with regulating endoplasmic reticulum stress.
作者 沈杰 王瑞环 苏国宏 Shen Jie;Wang Ruihuan;Su Guohong(Department of Hematology,Cangzhou Central Hospital,Hebei Cangzhou 061000,China)
出处 《现代肿瘤医学》 CAS 2019年第9期1500-1504,共5页 Journal of Modern Oncology
基金 沧州市科技支撑计划项目(编号:141302108)
关键词 硼替佐米 急性T淋巴细胞白血病 细胞凋亡 内质网应激 Bortezomib acute lymphoblastic leukemia cell apoptosis endoplasmic reticulum stress
  • 相关文献

参考文献1

二级参考文献32

  • 1Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies [ J ]. Blood, 2008,111(5) :2516 -2520.
  • 2Prince HM, Adena M, Smith DK, et al. Efficacy of single - agent bortezomib vs single - agent thalidomide in patients with relapsed or refractory multiple myeloma:A systematic comparisoin [ J ]. Eur J Haemato1,2007,79 (2) :93 - 99.
  • 3Mateos MV, Oriol A, Martinez Lopez J,et al. Bortezomib melpha-lan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with borte- zomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma : A randomised trial [ J ]. Lancet Oncol,2010,11 (10) :934 - 941.
  • 4Corthals SL, Kuiper R, Johnson DC, et al. Genetic factors underly- ing the risk of bortezomib induced peripheral neuropathy in multi- ple myeloma patients [ J ]. Haematologica, 2011,96 (11 ) : 1728 - 1732.
  • 5Richardson PG, Briemberg H, Jagannath S, et al. Frequency, char- acteristics, and reversibility of peripheral neuropathy during treat- ment of advanced multiple myeloma with bortezomib [ J ]. Clin On- col,2006,24(19) :3113 -3120.
  • 6Cavaletti G, Gilardini A, Canta A, et al. Bortezomib - induced pe- ripheral neurotoxicity:A neurophysiological and pathological study in the rat[J]. Exp Neurol,2007,204( 1 ) :317 -325.
  • 7Mateos MV. Management of treatment - related adverse events in patients with multiple myeloma [ J ]. Cancer Treat Rev, 2010,36 (2) :24 -32.
  • 8Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high - dose dexamethasone for relapsed multiple myeloma [ J ]. N Engl J Med,2005,352(24) :2487 - 2498.
  • 9San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus me]phalan and prednisone for initial treatment of multiple myelo- ma[ J]. N Engl J Med,2008,359(9) :906 -917.
  • 10Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus in- travenous administration of bortezomib in patients with relapsed muhiple mycloma : A randomised, phase 3, non - inferiority study [J]. Lancet Oncol,2011,12(5) :431 -440.

共引文献32

同被引文献40

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部